Granulomatosis With Polyangiitis

SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.

In this video, Rula Hajj-Ali, MD discusses her process for putting together a treatment plan for a vasculitis patient.

WASHINGTON — Alaska Native and American Indian populations demonstrate notably higher prevalences of ANCA-associated vasculitis vs. white patients, according to data presented at ACR Convergence 2024.

Patients with eosinophilic granulomatosis with polyangiitis and severe eosinophilic asthma showed significant improvements in asthma control and acute vasculitis symptoms after 1 year of benralizumab, according to real-world study results.

SAN DIEGO — Approximately two-thirds of patients with ANCA-associated vasculitis report having neurological involvement, according to data presented at ACR Convergence 2023.

SAN DIEGO — Patients with granulomatosis with polyangiitis and microscopic polyangiitis who lower their glucocorticoid dose have an increased risk for death, renal failure, progression or relapse, said a presenter at ACR Convergence 2023.

SAN DIEGO — Trimethoprim sulfamethoxazole prophylaxis halves serious infection risk in patients with granulomatosis with polyangiitis receiving B-cell depletion with rituximab, according to data presented at ACR Convergence 2023.

Physicians should screen patients for cocaine use before making a diagnosis of granulomatosis with polyangiitis, according to data published in Rheumatology Advances in Practice.